Daily Stock List
The Singing Machine Company, Inc. (SMDM)
Today we are highlighting The Singing Machine Company, Inc. (SMDM), here at the QualityStocks Daily Newsletter.
Based in Fort Lauderdale, Florida, The Singing Machine Company, Inc. develops and distributes a complete line of consumer-oriented karaoke machines and music under The Singing Machine™ and SoundX™ brand names. The Company is the first to provide karaoke systems for home entertainment in the United States. The Singing Machine sells their products in North America and Europe. Moreover, The Singing Machine Company is the first to offer digital music downloads for play on home karaoke machines. The Company lists on the OTC Bulletin Board.
The Singing Machine Company established in California concentrating on professional and semi-professional karaoke equipment. They engage in the design, development, distribution, marketing and sale of consumer-oriented karaoke systems, youth electronics, musical instruments, accessories and Music under The Singing Machine®, Bratz™, SMDigital™ and Motown® brand names.
Additionally, they produce and market karaoke music, including CD plus graphics (CD+G's), containing music and lyrics of popular songs for use with karaoke recording equipment. They contract for the reproduction of music recordings with independent studios. In 2009, The Singing Machine Company launched the online karaoke music download business through a partnership with content provider, Stingray Digital. The Singing Machine Company became the first karaoke company to provide legal karaoke downloads with an extensive selection of more than 8,000 karaoke titles.
In August, The Singing Machine Company announced the results for the Company's first fiscal quarter ended June 30, 2012. They announced net sales of approximately $1.76 million in the first quarter; this is almost identical to the $1.78 million reported for the same period the year prior. The Company indicated that the lack of change in net sales is attributable to the highly seasonal nature of karaoke sales.
The Company reported a gross margin of approximately 25.2 percent as compared to approximately 24 percent reported for the quarter ended June 30, 2011. Due to the slight increase in gross margin, the Company reported a slightly smaller First Quarter loss of approximately $480,000. This is in comparison to a net loss of approximately $508,000 in the same period the year prior.
The Singing Machine Company, Inc. (SMDM), closed Thursday’s session at $0.12, up 31.87%, on 200 volume with 1 trade. The average volume for the last 60 days is 33,767 and the stock's 52-week low/high is $0.02/$0.3949.
InSite Vision, Inc. (INSV)
Penny Performers, StockEgg, and Standout Stocks reported earlier on InSite Vision, Inc. (INSV), and we highlight the Company, here at the QualityStocks Daily Newsletter.
InSite Vision, Inc. is advancing new ophthalmologic products for unmet eye care needs. The Company develops novel ophthalmic products designed to treat a growing range of common eye problems. These include ocular infection, pain and inflammation in ocular surgery, and glaucoma. InSite Vision's shares trade on the OTC Bulletin Board. The Company has their corporate headquarters in Alameda, California.
InSite Vision's product portfolio utilizes their proven DuraSite® bioadhesive polymer core technology. This innovative platform extends the duration of drug retention on the surface of the eye. Therefore, this reduces frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite® system can be customized to deliver a wide array of potential drug agents.
DuraSite® is a drug delivery vehicle that stabilizes small molecules in a polymeric mucoadhesive matrix. The topical ophthalmic solution can be described as a gel forming drop. It extends the residence time of the drug relative to conventional eye drops. InSite Vision's DuraSite® platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb.
InSite Vision's clinical-stage ophthalmic product pipeline includes AzaSite Plus™ and DexaSite™ for the treatment of eye infections, BromSite™ for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. The Company's business strategy includes developing and extending their AzaSite® franchise in North America and internationally; advancing their late stage pipeline toward NDA filings; advancing their earlier stage pipeline toward Phase 3 clinical trials, and advancing their late pre-clinical pipeline toward Phase 1/2 clinical trials.
Their strategy also includes advancing their early pre-clinical pipeline toward IND-enabling GLP toxicology studies, seeking promising new late-stage products and technologies for in-licensing or acquisition, and executing on their plan with operational discipline.
In late September, InSite Vision announced that oral arguments are scheduled for November 6, 2012, in Washington, D.C. in connection with the University of California, San Francisco's (UCSF) appeal of the November 2011 favorable judgment of the United States Patent and Trademark Office (USPTO). The USPTO panel of judges ruled in favor of InSite Vision and confirmed the inventorship of the Company's U.S. Patent Nos. 6,239,113 and 6,569,443 protecting AzaSite® (azithromycin ophthalmic solution) 1%.
The appeal was filed by UCSF with the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. on December 23, 2011. A cross appeal was filed by InSite Vision on January 4, 2012. Merck, which markets AzaSite in the U.S. for the treatment of bacterial conjunctivitis, is collaborating with InSite on the continued vigorous defense of the AzaSite patents.
InSite Vision, Inc. (INSV), closed Thursday’s session at $0.38, up 7.04%, on 196,827 volume with 43 trades. The average volume for the last 60 days is 86,825 and the stock's 52-week low/high is $0.27/$0.54.
Carbon Sciences, Inc. (CABN)
MoneyTV, Greenbackers, TheLightningPicks, Beacon Equity Research, Stock Preacher, InvestorSoup, Stock Roach, and Penny Stocks Finder reported earlier on Carbon Sciences, Inc. (CABN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Carbon Sciences, Inc. is the provider of a complete solution for transforming abundant and affordable natural gas into gasoline that burns cleaner than petroleum-based gasoline. The engineering of the Company's solution is to cost effectively produce gasoline from the thousands of available small and medium size natural gas fields. Their first generation Gas-To-Liquids (GTL) solution integrates best of breed and proven technologies, including the ExxonMobil MTG process, to produce ready to use gasoline. Carbon Sciences lists on the OTCQB. The Company has their headquarters in Santa Barbara, California.
In addition, Carbon Sciences is developing a proprietary technology to enable a second-generation GTL solution that will produce even cleaner gasoline through using captured CO2 or low value, high CO2 content natural gas as part of the process. The Company's technology can also be used to transform natural gas into other valuable, large volume products. These include hydrogen, methanol, ammonia, solvents and plastics.
The key to this process is a patented, innovative catalyst that can reduce the cost of reforming natural gas into synthetic gas (syngas), the most costly step in making products from natural gas. Syngas is a gas mixture of carbon monoxide (CO) and hydrogen (H2).
The patented Carbon Sciences catalyst is a next generation natural gas reforming catalyst. It can reduce the cost and increase the production of syngas by significantly reducing the use of cost intensive steam; eliminating a capital intensive oxygen plant; using less energy, which reduces CO2 emissions, and consuming CO2 to enable, for the first time, the economical use of gas fields with high CO2 content.
In September, Carbon Sciences announced the results of an internal study that confirms the commercial viability of a U.S.-based project.
Mr. Byron Elton, Chief Executive Officer of Carbon Sciences, said," Our recently completed study indicates that a small to midsize natural gas-to-gasoline project could payback the initial capital expenditure in a little over 3 years. This is an extremely short payback period in the oil and gas industry and confirms the commercial viability of our project plan."
Carbon Sciences, Inc. (CABN), closed Thursday’s session at $0.80, up 12.68%, on 9,851 volume with 16 trades. The average volume for the last 60 days is 15,201 and the stock's 52-week low/high is $0.62/$3.00.
Liquidmetal Technologies, Inc. (LQMT)
Red Chip reported today on Liquidmetal Technologies, Inc. (LQMT), Jason Bond, UltimatePennyStock, Greenbackers, StreetInsider, Real Pennies, Stock Analyzer, All about trends, Trade of the Week did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Liquidmetal Technologies, Inc. is the leading developer of bulk alloys and composites that utilize the performance advantages offered by amorphous alloy technology. Liquidmetal Technologies is the first company to produce amorphous alloys in commercially viable bulk form. This is enabling significant improvements in products across a broad spectrum of industries. The Company's shares trade on the OTCQB. Liquidmetal Technologies is based in Rancho Santa Margarita, California.
Amorphous alloys are unique materials distinguished by their ability to retain a random structure when they solidify. This is in contrast to the crystalline atomic structure that forms in ordinary metals and alloys. Liquidmetal Technologies' innovative class of patented alloys and processes form the basis of high performance materials used in a wide array of medical, military, consumer, and industrial and sporting goods products. Liquidmetal Technologies controls the intellectual property (IP) rights with over 50 U.S. patents.
Pertaining to performance, the Company's alloys are, in numerous cases, stronger, harder, more elastic, and more wear and corrosion resistant than commonly used high-performance alloys. Their "bulk" amorphous alloys possess advantages generally associated with plastics; this includes the ability to undergo molding into precision, complex, and highly finished products.
Liquidmetal has 2-3 times the strength of titanium and stainless steel. They undergo processing similar to plastics on the Company's proprietary Liquidmetal molding machines. Liquidmetal is processed and solidified in a vitreous or amorphous state (frozen liquid).
Recently, Liquidmetal Technologies formally introduced Nomad Sales as the Company's sales representative firm in the Midwest region of the United States. Nomad Sales will be promoting Liquidmetal amorphous alloys for commercial markets including aerospace, medical and industrial products. Nomad Sales, headquartered in the Twin Cities area of Minneapolis, Minnesota, is an independent manufacturer's representative firm recently founded by their two senior partners, Mr. Jim Morris and Mr. Charlie Reese. Nomad Sales established to represent manufacturers whose products are made using plastic injection molding; aluminum and zinc die casting, rotational molding and precision machining.
Liquidmetal Technologies, Inc. (LQMT), closed Thursday’s session at $0.1672, up 5.16%, on 800,282 volume with 135 trades. The average volume for the last 60 days is 1,103,060 and the stock's 52-week low/high is $0.1151/$0.6349.
Peregrine Pharmaceuticals, Inc. (PPHM)
PhD-Trading reported this week on Peregrine Pharmaceuticals, Inc. (PPHM), StreetInsider, Penny Stock Rumble, Stock Analyzer, OTCPicks, InvestorPlace, HoleinOneStocks.net, PennyStockCrowd, The Street, AimHighProfits, SmarTrend Newsletters, Greenbackers did earlier, and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Tustin, California, Peregrine Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Peregrine has a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. Their clinical pipeline includes bavituximab, a first-in-class monoclonal antibody with demonstrated broad-spectrum potential in cancer and viral diseases, and Cotara®, their novel brain cancer therapy. Both bavituximab and Cotara are currently in Phase II clinical development. The Company's shares trade on the NASDAQ Capital Market.
Peregrine Pharmaceuticals also has in-house cGMP manufacturing capabilities by way of their wholly owned subsidiary Avid Bioservices, Inc. Avid Bioservices provides development and biomanufacturing services for both Peregrine and outside customers. For oncology indications, Peregrine's lead phosphatidylserine (PS)-targeting candidate bavituximab in combination with chemotherapy has demonstrated promising signs of anti-tumor activity in patients with non-small cell lung cancer (NSCLC) and advanced breast cancer.
The Company, based on these encouraging results, is currently conducting three randomized Phase II trials in different oncology indications. For viral infection indications, bavituximab has undergone evaluation in combination with ribavirin in a randomized Phase II trial in 66 treatment naive patients with genotype-1 hepatitis C virus (HCV) infection. The compound is also undergoing assessment in four investigator-sponsored trials in additional oncology indications.
Cotara is the Company's lead Tumor Necrosis Therapy (TNT) agent. It is currently undergoing evaluation in a Phase II clinical trial in glioblastoma multiform (GBM) patients at first relapse. Cotara targets necrotic cells at the core of solid tumors. It transports and binds radioactive iodine to the center of the tumor, allowing the radiation to destroy the tumor from the inside out.
Recently, Peregrine Pharmaceuticals announced that they changed the location of their Annual Meeting of Stockholders to be held on October 18, 2012 at 10:00 a.m. Pacific Daylight Time. The new location is the Wyndham Orange County Hotel, 3350 Avenue of The Arts, Costa Mesa, California 92626.
Peregrine Pharmaceuticals, Inc. (PPHM), closed Thursday's trading session at $0.77, down 1.03%, on 6,203,877 volume with 7,554 trades. The average volume for the last 60 days is 8,407,399 and the stock's 52-week low/high is $0.39/$5.50.
Source Gold Corp. (SRGL)
PennyTrader Publisher, and Pumps and Dumps reported this week on Source Gold Corp. (SRGL), Top Gun, The Stock Psycho, SimplyBestPennyStocks, HotShotStocks, Bullseyestox.com, Penny Stock Day Trades, and Top Best Pennystocks did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 2008, Source Gold Corp. is a junior mineral exploration company that lists on the OTCQB. The Company focuses on the exploration and development of high quality mining and exploration projects in Canada and the United States. They explore for gold, silver, and other metals. The Company was formerly known as IBEX Resources Corp. They changed their name to Source Gold Corp. in August of 2009. Source Gold has their headquarters in Toronto, Ontario.
The Company is concentrating on gold in the prolific Southern Beardmore Gold Camp in North Western Ontario, and expanding utilizing advanced methods of exploration on the once prolific silver and gold producer, the Vulture Mine Site, in Wickenburg, Arizona.
The claims in the Vulture Property are located on property whose geology and mineralization have proven historically positive. The Company has concluded that the property is of merit and possesses good potential for the discovery of gold and silver. Source Gold holds 100 percent ownership of all the claims. The 23 properties (with a total property area of 476.1 acres) are either contiguous to, or near to the historically famous Vulture Mine.
Source Gold owns a group of 21 contiguous mineral claims covering an area of 269 hectares in the Beardmore and Mary Jane Lake areas located near Beardmore, Ontario. The Company has their KRK West Prospect in Beardmore. The Property location is the area of major discoveries, including the Hercules Discovery and the Leitch Mine. Sampling shows gold occurrences identified by previous prospecting of 9.55 ounces of gold per ton and 15.5 percent copper in separate grab samples.
Yesterday, Source Gold announced that they entered into final negotiations to acquire a privately held mineral lease holding Company. The primary asset of the private holding company is approximately 10,000 contiguous hectares of 100 percent title interest Gold and Silver leases. These are located in the municipality of Mascota, at an elevation of between 1600 and 2200 meters above sea level. It is accessible from Guadalajara, Jalisco, Mexico via a 135 km-long paved highway to the town of Mascota then northeast 10km on gravel roads to the small town of Natividad, drivable year-round.
Source Gold Corp. (SRGL), closed Thursday's trading session at $0.042, up 16.99%, on 1,780,559 volume with 146 trades. The average volume for the last 60 days is 466,732 and the stock's 52-week low/high is $0.0041/$0.25.
Waymar Resources Ltd. (WYM.V)
Today we are highlighting Waymar Resources Ltd. (WYM.V), here at the QualityStocks Daily Newsletter.
Waymar Resources Ltd. is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company has an option to acquire 100 percent interest in the Anza project located in the west of the Antioquia Department in the Republic of Colombia. Waymar also has 100 percent ownership of certain properties surrounding Anza that cover the district's mineral potential. The Company is continually looking for opportunities to acquire exploration properties. Waymar Resources is based in Vancouver, British Columbia. The Company has an exploration office located in Medellin, Colombia.
Upon exercise of the option in the Anza project, the optionors will retain a 2 percent Net Smelter Return (NSR) royalty on that portion of the Anza property governed by the Option Agreement, one-half of which may be purchased by Waymar Resources for a cash payment of US$1,000,000. The Anza project is on the eastern-most margin of Colombia's Western Cordillera, 50km west of Medellin, Colombia, covering approximately 25,966 hectares.
The Company acquired the interest in the Anza project pursuant to an agreement effective June 29, 2010 (Anza Property Option Agreement). They entered into an option to acquire a 100 percent interest in the Anza project of approximately 6,738 hectares of mineral rights.
This week, Waymar Resources reported significant results from five additional diamond drill holes on their Anza deposit, Antioquia Department, Colombia. These holes are part of an overall drilling program that continues to expand the Anza deposit along the Aragon fault and to identify and delineate high-grade gold and silver mineralization.
Drill Hole MAP-48 was drilled from the west to test the continuity and thickness of the high-grade gold zone intersected in MAP-33, MAP-20, MAP-42, MAP-11 and MAP-24. This zone now extends over at least 140 m strike-length. Significant intercepts include 14.7 m of 40.3 g/t Au, including 10.2 m of 58.0 g/t Au and 1.9 m of 219.0 g/t Au; 2.2 m of 7.8 g/t Au.
Drill hole MAP-47 is between drill holes MAP-29 and MAP-14, approximately 150 m south of the La Pastorera gypsum mine. It encountered numerous mineralized zones in the hanging-wall of the Aragon fault. The most significant intercept shows a zone of high-grade silver coincident with gold, as follows: 13.3 m of 2.2 g/t Au and 316.3 g/t Ag, including 4.5 m of 4.7 g/t Au and 768.9 g/t Ag.
Drill hole MAP-46 is 40 m north of MAP-29 and approximately 80 m south of the La Pastorera gypsum mine. It encountered several zones of shallow mineralization, including 10.5 m of 2.7 g/t Au, including 1.5 m of 6.1 g/t Au; 8.7 m of 2.3 g/t Au, including 1.5 m of 8.6 g/t Au; 4.8 m of 4.0 g/t Au, including 1.5 m of 10.6 g/t Au.
Waymar Resources Ltd. (WYM.V), closed Thursday's trading session at $0.45, up 4.65%, on 200,000 volume. The stock's 52-week low/high is $0.21/$0.70.
Xtra-Gold Resources Corp. (XTGR)
BabyBulls, La Quinta Resources, Stock Guru, and SmallCapVoice reported previously on Xtra-Gold Resources Corp. (XTGR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Xtra-Gold Resources Corp. is a resource enterprise with a placer gold mining opportunity and an active lode gold exploration program in Ghana, West Africa. The Company is working towards gold production; they are continuing to investigate gold exploration targets in a highly prospective gold belt analogous to the Ashanti Gold Belt. Xtra-Gold Resources has their corporate headquarters in Toronto, Ontario.
Ghana is home to some of the world's largest gold mines. These include Anglo-Ashanti's Obuasi Mine and Goldfields' Tarkwa Mine.
To date, more than 140 million ounces of gold has undergone discovery in Ghana. This includes over 20 million ounces of gold discovered by Newmont Mining Corp. since 2002 at their Akyem and Ahafo deposits.
Xtra-Gold Resources is focusing on defining a potentially significant resource on their Kibi Gold Discovery in the Republic of Ghana, West Africa. Xtra-Gold has a dominant land position in the highly prospective Kibi Greenstone Belt. It is the last greenstone belt to undergo drilling and development in Ghana. Xtra-Gold holds the mineral rights to 5 concessions, totaling 226 square kilometers (22,600 hectares), located in the Kibi Gold Belt. The Company made a gold discovery on their southern most property - the Apapam Concession (the Kibi Gold Discovery). Xtra-Gold is conducting an aggressive drill program on their Apapam Concession (Kibi Project).
Concerning the Kibi Gold Discovery, the Company indicates that drilling has yielded encouraging results and demonstrates that the granitoid-hosted mineralization offers potential for shallow oxide mineralization amenable to bulk mining and heap leaching, as well as a large primary gold system at depth. The soil geochemistry and trenching identified four high-grade zones. Earlier drilling focused on Zone 2 to define multiple gold shoots. The Company's intention is to drill the other three high-grade zones. Their objective is increasing the size of the gold mineralization.
In August, Xtra-Gold Resources announced results from 53 additional diamond core holes totaling 8,810 meters (m) from their wholly owned Kibi Gold Project. Drilling efforts include 17 holes designed to further test/delineate the high-grade Double 19 shoot (Zone 3 - East) and the South Ridge zone (Zone 2), and 36 scout drill holes to test geochemical/geophysical anomalies, geological targets, and the Kibi Old Mine prospect.
In early September, Buccaneer Gold Corp. announced further drill core assay results from their 2012 drill program at the Muoso and Banso Concessions, located within the Kibi Gold Belt, in the Eastern Region, Ghana, West Africa. These concessions are under option from Xtra-Gold Resources.
Xtra-Gold Resources Corp. (XTGR), closed Thursday's trading session at $0.88, up 1.15%, on 3,360 volume with 3 trades. The average volume for the last 60 days is 29,526 and the stock's 52-week low/high is $0.66/$1.71.
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $4.20, up 6.33%, on 46,458 volume with 62 trades. The stock’s average daily volume over the past 60 days is 61,001, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. reported taking another bold step today with the signing of an agreement between the company and Pharmaceutical Care Consultants of South Florida (d/b/a Skip's Pharmacy), whereby Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua. The eminent Dr. Lenz will head up the company's global manufacturing development, reporting directly to TNIB CEO, Noreen Griffin, as he applies his extensive clinical research expertise alongside longtime partner Phil Giordano, who have together made Skip's Pharmacy the number one outlet for the IRT-103 (LDN) treatment over the last decade.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital
TNI BioTech, Inc. Signs Memorandum of Agreement to Open Pharmaceutical Plant for the Production of IRT-103 (LDN)
GreeneStone Healthcare Corp. (GRST)
The QualityStocks Daily Newsletter would like to spotlight GreeneStone Healthcare Corp. (GRST). Today, GreeneStone Healthcare Corp. closed trading at $1.82, up 2.82%, on 70,876 volume with 66 trades. The stock’s average daily volume over the past 60 days is 13,508, and its 52-week low/high is $0.70/$1.78.
GreeneStone Healthcare Corp. (GRST) is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.
Ontario's public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.
Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.
The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry. Disclaimer
GreeneStone Healthcare Corp. Company Blog
GreeneStone Healthcare Corp. News:
GreeneStone Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
GreeneStone Supports the Cause of Mental Health with Charitable Foundation
GreeneStone Muskoka Once Again Featured on Intervention Canada
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.60, up 9.09%, on 22,706 volume with 7 trades. The stock’s average daily volume over the past 60 days is 7,152, and its 52-week low/high is $0.43/$1.87.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Announces New Channel Partnership With Level Seven
GlobalWise Announces Appointment of Kendall D. Gill to Chief Financial Officer Position
MissionIR Features GlobalWise in Exclusive Interview Featuring CEO William Santiago
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.28, up 10.67%, on 84,441 volume with 17 trades. The stock’s average daily volume over the past 60 days is 133,266, and its 52-week low/high is $0.21/$0.835.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
International Stem Cell Corp to Participate in Upcoming Investor Conference
International Stem Cell Corp Granted Key Patent for Liver Disease Program
TNI BioTech, a biotech company combating fatal diseases through the activation and mobilization of the body’s immune system, announced this morning that it has entered an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip’s Pharmacy. As a result of this agreement, Dr. Henry “Skip” Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for its pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for spearheading the company’s global manufacturing development.
Joining TNI BioTech’s executive leadership team, Dr. Lenz will be responsible for making sure all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance, and production for multiple international manufacturers. Furthermore, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company that secured over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years, Dr. Lenz has concentrated his efforts on relieving HIV/AIDS by participating in clinical applications of several novel therapies.
Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip’s Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip’s Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient’s needs. Skip’s Pharmacy has been the leading outlet for the supply of LDN for over ten years.
Noreen Griffin, TNI BioTech’s CEO, underscored the company’s unwavering dedication to delivering a quality product and becoming a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.
Dr. Lenz stated, “I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone.”
For additional information, visit the company’s website at www.TNIBiotech.com
GreeneStone Healthcare is focused on operating medical and healthcare clinics in Ontario, Canada, offering addiction treatment, colonoscopy, endoscopy, minor cosmetic procedures, and executive health assessment programs. The company adds overflow capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly underserviced healthcare needs.
Ontario’s public healthcare cost has grown at a compounded 7.1% rate over the past 10 years, now accounting for approximately $77B in government spending compared to $39B in 2000. This cost explosion is similar for the country as a whole, growing at 7.4% over the same period. The need for practical change to the system is immediate as demand continues to rise.
Governments are increasingly looking to private alternatives to address the growing trade-off between costs vs. service in the public healthcare system. Private services are expanding beyond their traditional place as overflow capacity to relieve wait times. GreeneStone Healthcare is particularly well positioned with a first-mover advantage in mental healthcare – a highly underserviced niche.
The company currently offers its various medical services via three medical clinics. Future plans include establishing partnerships for accelerated growth as well as dual-listing on CNSX. With positive revenue growth and cash flow positive status recently achieved, GreeneStone is methodically extending its vertical expertise in the healthcare industry.
Cardium Therapeutics is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company’s in-house MedPodium Health Sciences healthy lifestyle product platform.
The company’s lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product’s commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium’s lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team’s skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value.
Let us hear your thoughts: Cardium Therapeutics, Inc. Message Board
Today, Elbit Imaging Ltd. announced that on Oct. 10, Elbit Medical Technologies Ltd. (90 percent held by Elbit Imaging) and InSightec Ltd. (64.3 percent held by Elbit Medical and 53 percent held on a fully diluted basis) entered into a share purchase agreement with GE Healthcare and certain other shareholders of InSightec. Pursuant to the investment agreement, GE and the other investors will invest an amount totaling around $31.4 million in InSightec.
According to the main terms of the transaction, GE will invest $22.5 million in cash and convert its $5 million convertible loan, which it provided to InSightec in June of 2012, in exchange for InSightec’s series C preferred shares. The other investors will simultaneously invest around $3.9 million in cash in consideration for InSightec’s series C preferred shares. GE and Elbit Imaging will also convert all outstanding shareholder loans that have been granted to InSightec into InSightec’s B-1 preferred shares, in accordance with the terms of those kinds of loans.
This transaction reflects a post-money valuation of about $104.6 million for InSightec, or a pre-money valuation of $75 million. GE and InSightec, as part of the agreement, have reached written understandings regarding the commercial relationship between them, including the distribution and marketing of InSightec’s products, development of those products to make them exclusively fit GE’s MRI for a certain period of time, mutual technical assistance, grant of licenses, and other considerations. This will be recorded in a definitive technology, co-operation, and distribution agreement. The finalization of the transaction will be subject to several conditions, including receipt of certain regulatory approvals and the execution of the definitive technology, co-operation, and distribution agreement.
Once the transaction has closed, Elbit Medical’s holdings in InSightec will be reduced to about 48 percent and 41 percent on a fully diluted basis. Elbit Medical will also no longer have the right to appoint the majority of InSightec’s directors and will, therefore, cease to consolidate InSightec’s financial statements. Additionally, it is anticipated that Elbit Medical will record a significant – but at this time indeterminable – gain when the transaction closes.
After the initial closing of the transaction, pursuant to the investment agreement and for a period of 90 days afterward, Elbit Imaging will have the option to purchase all the series C preferred shares of InSightec that were purchased by GE and its affiliates for $22.5 million in cash, as well as all or any portion of the series C preferred shares, in consideration of cancellation of indebtedness of Elbit Imaging by GE (amounting to $5 million) plus accrued interest at the time of the conversion. Any purchase would take place following a separate purchase and sales agreement at the series C purchase price per share for both purchased shares and conversion shares.
Elbit Imaging operates in the principal business fields of commercial and entertainment centers, U.S. real property, hotels, medical industries, residential products, fashion apparel, and other activities, including venture capital investments and potential investments in hospitals and farm and dairy plants in India. The company is currently suspending its investment activities in hospitals and farm and dairy plants in India until the economy has sufficiently recovered so that these activities can be resumed.
For more information, visit the company’s Web site at www.elbitimaging.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Cardium Therapeutics, Inc. (CXM) Announces the Acquisition of To Go Brands
- Consorteum Holdings, Inc. (CSRH) Subsidiary, Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming with the Acquisition of To Go Brands
- GlobalWise Investments, Inc. (GWIV) Announces New Channel Partnership With Level Seven
- GreeneStone Healthcare Corp. (GRST) Implementing 'Build & Buy' Growth Strategy To Capitalize On Huge Opportunity In Behavioral Treatment
- International Stem Cell Corp. (ISCO) Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
- Loans4Less.com, Inc. (LFLS) New Audio Interview With Mr. Steven M. Hershman, Chairman and CEO via SmallCapVoice
- MusclePharm Corp. (MSLP) MusclePharm Wins Three Bodybuilding.com Awards Upon Fitness Enthusiasts' Votes
- Skinny Nutritional Corp. (SKNY) to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+
- Teletouch Communications, Inc. (TLLE) Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
- TNI BioTech Inc. (TNIB) Dr. Henry "Skip" Lenz, Pharm.D, Joins the Company as Quality Control Officer
- VistaGen Therapeutics, Inc. (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund